Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation, Cellular Therapy, or Gene Therapy

* INCLUSION CRITERIA FOR PATIENT SUBJECTS: * Individuals who underwent HCT or received cellular or gene therapy for any indication (malignant or non-malignant) and are surviving one year or more from the date of therapy * Age \>= 4 years * Ability of individual or individual s Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document * Individuals will need to have a primary physician within the US (primary care, oncologist, hematologist, etc.) that will provide continued comprehensive care for the duration of participation in the study. PI may allow for established medical providers to be located outside of the US. EXCLUSION CRITERIA FOR PATIENT SUBJECTS: -Individuals with active disease relapse or new hematologic malignancy including post-transplant lymphoproliferative disorder (PTLD) are excluded from protocol enrollment. INCLUSION CRITERIA FOR DONOR SUBJECTS: * Related stem cell donors of patients meeting the above criteria as a donor of hematopoietic progenitor and stem cells or leukocytes * Age \>= 4years * Ability of patient or patient s Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document INCLUSION CRITERIA FOR PARENTS COMPLETING SURVEYS: * Parents/guardians of minors enrolled on the study who have undergone HCT * Willingness to complete surveys about the minor that underwent HCT